Introduction
============

Macrophages are highly plastic monocyte-derived cells that acquire different molecular and functional phenotypes following exposure to different bioactive molecules and environments. The early studies on the interactions of macrophages and lymphocytes in battling bacterial infections revealed the T helper type 1 (Th1) secreted cytokine IFNγ to be involved in the classical activation of macrophages (Nathan et al., [@B44]). However, seminal studies by the groups of Gordon and Mantovani have extensively characterized additional macrophage subtypes activated in alternative manners (reviewed in Mantovani et al., [@B36]; Martinez et al., [@B37]). Since the major polarizing cytokines initially found to be involved in classical and alternative activation were derived from Th1 (IFNγ) and Th2 (IL-4 and IL-13) lymphocytes these activated macrophages were named M1 and M2, respectively. Later studies revealed that in addition to IL-4, alternative activation can also be induced by immune complexes and glucocorticoids (Martinez et al., [@B38]), and accordingly the subdivision of alternatively activated macrophages to M2a--c was instilled. M1 macrophages are important inducers and effectors in the Th1 response. They are instrumental in immune responses against intracellular microbes and tumors (Mantovani et al., [@B35]). M2 macrophages are more heterogeneous, but generally play a role in Th2 responses, such as killing and encapsulation of extracellular parasites, resolving type 1 inflammation, and promoting tissue repair and remodeling. M2 macrophages are also playing a role in immune regulation and promote tumor progression (Mantovani et al., [@B35]; Martinez et al., [@B37]). M1 and M2 macrophages are not only distinct in function, but also express different receptors and enzymes required for their activities. M1 macrophages express high levels of inflammatory cytokines (IL-12, IL-23, TNFα, IL-1β, and IL-6) and chemokines (CXCL9, 10, and 11, CCL2, 3, 4, and 5, and CXCL2), as well as enzymes involved in the generation of reactive oxygen species (ROS) and nitric oxide (NO; Mantovani et al., [@B35]). M2 macrophages express lower levels of inflammatory mediators, but high levels of IL-10, scavenger, mannose, and galactose receptors. Importantly, in mice, M2 express the enzyme arginase-1 that intercepts the NO generation pathway \[though inducible NO synthase (iNOS)\] to generate ornithine and polyamines that are instrumental in tissue repair and fibrosis (Hesse et al., [@B20]). Hence, the expression of iNOS and arginase-1 are major markers deciphering M1 and M2 macrophages. Additional markers of M2, such as YM1 and FIZZ1, were later identified in mouse macrophages (Raes et al., [@B50], [@B51]).

Macrophages also undergo dramatic molecular and functional changes upon encounter, interaction with, and uptake of apoptotic cells (efferocytosis) during the resolution of inflammation. In this article we will highlight some of the similarities between M2 differentiation and transcriptional events activated by early efferocytosis. In addition, we will discuss recent results that support the notion that efferocytosis can eventually transform macrophages to another phenotype that is postulated to limit tissue repair/fibrosis and promote macrophage regulatory properties at remote sites. In this regard, it is important to note the early studies that indicated "non-phlogistic" activation of monocytes by the pro-resolving lipid mediators lipoxins. This bioactivity of lipoxins resulted in increased adhesion and migration of human monocytes (Maddox and Serhan, [@B34]; Maddox et al., [@B33], [@B32]) hence prompting the notion that resolution-driven monocyte/macrophage activation promotes tissue repair and wound healing.

Efferocytosis as an Alternative Mode of Macrophage Activation
=============================================================

The recognition, engulfment, and responsiveness to apoptotic cells are cardinal properties of resident and inflammatory macrophages and play a role in processes, such as tissue morphogenesis and homeostasis, embryonic development, hematopoiesis, immunity, and the resolution of inflammation (Savill et al., [@B54]; Erwig and Henson, [@B12]; Ravichandran and Lorenz, [@B53]). The recognition and uptake of apoptotic cells by macrophages through "eat me" signals (and the absence of "do not eat me" signals) expressed on their surface and their cognate receptors have been extensively studied and reviewed (Ravichandran, [@B52]). However, apoptotic cells also transduce signals to the engulfing macrophages that result in significant molecular and functional adjustments that address physiological needs consequent to the identified cell death. During the resolution of inflammation, macrophages engulf apoptotic cells and consequently, apoptotic cell recognition evokes distinct signaling events (Patel et al., [@B47]) that block the release of pro-inflammatory mediators from macrophages. This release is activated by bacterial moieties, and its blockage, which is termed immune-silencing (Voll et al., [@B62]; Fadok et al., [@B13]; Kim et al., [@B27]), is accompanied by the production of TGFβ and IL-10 (Byrne and Reen, [@B8]; Huynh et al., [@B23]; Mitchell et al., [@B41]), cytokines that can promote resolution and wound repair. The engulfment of apoptotic leukocytes by macrophages also leads to inhibition of iNOS expression and stimulates the expression of arginase-1 in the RAW 264 macrophage cell line (Freire-De-Lima et al., [@B16]) thereby preventing reactive NO production. In addition, the production of angiogenic growth factors (Golpon et al., [@B18]) by macrophages is consequent to the uptake of apoptotic cells. Elucidation of the signaling pathways activated by efferocytosis revealed significant roles for nuclear transcriptional regulators, such as peroxisome proliferator activated receptor (PPAR)-γ (Freire-De-Lima et al., [@B16]; Johann et al., [@B24]) and -δ (Mukundan et al., [@B42]) as well as the liver X receptor (LXR; A-Gonzalez et al., [@B1]) in promoting anti-inflammatory properties.

It is important to note that while macrophages engulf tissue-infiltrating apoptotic PMN during the resolution of inflammation, different experimental models used different sources of apoptotic cells, including Jurkat T cells, mouse thymocytes, or human peripheral blood neutrophils. All types of apoptotic cells express phosphatidylserine on the outer leaflet of their cytoplasmic membrane, and this is apparently the major signaling module used by these cells to communicate their mortal status with phagocytic cells (Ravichandran, [@B52]). Nevertheless, it is conceivable that other molecules ("eat me signals") are expressed on apoptotic cells of different sources to give a more detailed "report" as to the consequences of their demise. Thus, the interpretation of the results obtained following incubations of macrophages with apoptotic cells of different sources should be evaluated carefully depending on the source of apoptotic cells used.

The prototypic Th2 cytokines IL-4, IL-13, and IL-10, as well as immune responses to parasites were found to promote many of the outcomes of efferocytosis in macrophages. These cytokines are well appreciated antagonists of the M1 response and macrophage pro-inflammatory properties (Martinez et al., [@B37]) while IL-4 and IL-13 can also promote fibrosis through TGFβ production (Fichtner-Feigl et al., [@B15]; Wynn, [@B64]). IL-13 was also found to promote vascular endothelial growth factor production during lung injury (Corne et al., [@B10]). Importantly, IL-4 and IL-13 also activate PPAR-γ (Huang et al., [@B22]; Berry et al., [@B6]) and PPAR-δ (Kang et al., [@B25]) to promote monocyte/macrophage alternative activation. LXR was recently found to synergize with IL-4 in the induction of arginase-1 expression and promotion of an M2 phenotype in regressive atherosclerotic lesions (Pourcet et al., [@B49]). Thus, efferocytosis induces phenotypic and molecular switches and activates signaling pathways in macrophages that resemble M2 polarization. Moreover, M2 polarization promotes efferocytosis through induction of different molecular modules, whereas M1 macrophages exert reduced uptake of apoptotic cells. Along these lines, recent studies also found that efferocytosis is a self-promoting process, and that M2 pathways play key roles in mediating this feature of macrophage function. These aspects of efferocytosis are covered by Korns et al. ([@B28]) in this research topic and will not be elaborated on here. Nevertheless, while macrophages are paradoxically involved in both the generation of fibrosis and its resolution (Wynn and Barron, [@B65]) and efferocytosis and M2 polarization generate a positive feedback loop during resolution of inflammation, it is much less clear what are the events and mediators that stop M2 differentiation and tissue repair/remodeling short of excessive, fibrotic outcomes. Such events and mediators are inevitably required to complete the resolution of inflammation and restore homeostasis rather than end every infection with a debilitating scar.

15-lipoxygenase and its products
--------------------------------

A major enzymatic pathway that mediates key events in the resolution of inflammation involves the expression and activation of 12/15-lipoxygenase (LO) in mice and 15-LO-1 in humans. 15-LO expression and activity are upregulated by IL-4 and IL-13 in murine and human monocytes, macrophages, and peripheral blood mononuclear cells (Levy et al., [@B30]; Nassar et al., [@B43]; Heydeck et al., [@B21]; Huang et al., [@B22]; Ariel et al., [@B4]). This upregulation leads to the production of 15-LO products from eicosatetraenoic and docosahexaenoic acids (ETA and DHA, respectively), such as 15-hydroxyeicosatetraenoic acid (15-HETE), lipoxin (LX) A~4~ and B~4~ (5*S*,6*S*,15*S*-trihydroxy-7*E*,9*E*,11*Z*,13*E*-EPA, and 5*S*,14*R*,15*S*-trihydroxy-6*E*,8*Z*,10*E*,12E-EPA, respectively), 17*S*-hydroxy-DHA (17*S*-hydroxy-4*Z*,7*Z*,10*Z*,13*Z*,15*E*,19*Z*-DHA), and protectin D1 (10*R*,17*S*-dihydroxy-4*Z*,7*Z*,11*E*,13*E*,15*Z*,19*Z*-DHA). Macrophage expression of 12/15-LO was found to promote the production of resolvin (Rv) D1 (7*S*,8*R*,17*S*-trihydroxy-4*Z*,9*E*,11*E*,13*Z*,15*E*,19*Z*-DHA) and maresin 1 (7,14-dihydroxy-4*Z*,8,10,12,16*Z*,19*Z*-DHA), in addition to LXA~4~ and PD1 (Merched et al., [@B40]; Serhan et al., [@B59]). The expression of 12/15-LO was also found to be upregulated in mouse macrophages following their incubation with apoptotic cells (Freire-De-Lima et al., [@B16]; Schif-Zuck et al., [@B55]) and resulted in the production of 15-HETE and LXA~4~ (Freire-De-Lima et al., [@B16]). Macrophages from chronic granulomatous disease (CGD) mice display impaired efferocytosis that could be repaired by IL-4 through the expression of 12/15-LO and activation of PPAR-γ (Fernandez-Boyanapalli et al., [@B14]). Hence, 15-LO-mediated signaling seems to be a major convergence point for efferocytosis and M2 polarization, and its down-stream signaling pathways could play a paramount role in deciphering whether macrophages will become pro-fibrotic or will finalize the resolution sequel to restore tissue homeostasis.

Along these reasoning, 12/15-LO products have been shown to be anti-inflammatory and to promote tissue repair, while playing an anti-fibrotic and immune-regulatory role (Serhan, [@B57]). The major bioactive 12/15-LO products could be produced from arachidonic acid to yield 15-HETE or lipoxins, or from DHA to generate protectin D (PD)1, resolvins of the D series, and the recently identified macrophage product maresin 1 (Serhan, [@B57]). While 15-HETE binds PPARγ to mediate its anti-inflammatory actions (Huang et al., [@B22]), LXA~4~, PD1, and resolvin D1 seem to act through binding to cell surface GPCRs (Serhan et al., [@B58]), as well as the aryl hydrocarbon receptor (that binds LXA~4~; Machado et al., [@B31]). All these 12/15-LO products induce a broad spectrum of anti-inflammatory actions on neutrophils and macrophages, as well as other cell types (Wittwer and Hersberger, [@B63]; Serhan et al., [@B58]). Lipoxins and PD1 are produced during epithelial injury in the cornea and mediate wound repair in addition to counteracting inflammation (Gronert et al., [@B19]). On the other hand, 12/15-LO products also induce unique pro-resolving properties of macrophages and promote regulatory pathways in lymphocytes. LXA~4~, PD1, RvD1, and PPARγ agonists were all found to promote efferocytosis and enhance PMN clearance during resolution (Godson et al., [@B17]; Schwab et al., [@B56]; Fernandez-Boyanapalli et al., [@B14]; Krishnamoorthy et al., [@B29]). In addition, PD1 and RvD1 were found to promote macrophage departure of resolving inflammation sites (Schwab et al., [@B56]; Schif-Zuck et al., [@B55]). LXA~4~ and PD1 inhibited inflammatory cytokine secretion from T lymphocytes (Ariel et al., [@B2], [@B4]) and enhanced CCR5 expression on apoptotic PMN to promote clearance of its pro-inflammatory ligands (Ariel et al., [@B3]). Moreover, LXA~4~ was recently found to play a role in the generation of myeloid-derived suppressor cells (Zhang et al., [@B66]). Of note, LXA~4~, PD1, and RvD1 are potent inhibitors of fibrosis in the lung and kidney (Duffield et al., [@B11]; Martins et al., [@B39]; Borgeson et al., [@B7]). Therefore, 15-LO products can be generated by macrophages following their interaction with apoptotic cells and/or polarization to the M2 phenotype. In turn, these products not only block inflammation but can also shift the macrophage healing balance from tissue repair/fibrosis to pro-resolution, anti-fibrotic, and regulatory functions. The exact mode of production and action for the different 15-LO products is probably dependent on substrate availability, concentration formed in the healing tissue and additional cues from the resolving environment. Nevertheless, they seem to act in concert to promote post-inflammation tissue healing and return to homeostasis.

CD11B^low^ Macrophages -- A New Phenotype Generated Following Satiated-Efferocytosis
====================================================================================

Recent reports have indicated the co-existence of various macrophage phenotypes in resolving peritoneal cavities (Bystrom et al., [@B9]; Schif-Zuck et al., [@B55]). Macrophages from resolving murine peritonitis expressed an alternatively activated phenotype albeit with increase expression of M1 markers, such as cyclooxygenase 2 (COX 2) and iNOS (Bystrom et al., [@B9]). Thus, these macrophages were termed resolution-phase macrophages (rMs) and were postulated to have a hybrid phenotype of classically and alternatively activated macrophages (Bystrom et al., [@B9]). A recent report from the same group has indicated that rMs could be divided to at least three distinct populations based on F4/80 and Ly-6C expression, with varying expression of additional pro-inflammatory and anti-inflammatory markers as well as CD11b (Stables et al., [@B60]). Along these lines, we have recently characterized F4/80^+^ macrophages from resolving peritoneal exudates into two distinct macrophage subtypes: CD11b^high^ and CD11b^low^ (Schif-Zuck et al., [@B55]). CD11b^high^ macrophages were found to express low to intermediate levels of the M1 markers iNOS, COX 2, and matrix metalloproteinase (MMP)-9 and high levels of the M2 marker arginase-1. These cells also expressed very low levels of 12/15-LO. In addition, these macrophages secret medium levels of inflammatory cytokines and chemokines, as well as IL-10, in response to TLR ligands, are highly phagocytic, and do not migrate to lymphoid tissues. CD11b^low^ macrophages express even lower levels of iNOS, COX 2, and MMP-9 than CD11b^high^ ones, but they also do not express arginase-1. In addition, these macrophages secrete very low levels of inflammatory cytokines and chemokines, and IL-10, but higher amounts of TGFβ. Moreover, CD11b^low^ macrophages, despite containing higher numbers of apoptotic PMN, are no longer phagocytic and are prone to emigrate to remote sites. Hence, CD11b^low^ macrophages were termed "satiated" (Schif-Zuck et al., [@B55]). A seminal report from Ravichandran and colleagues (Park et al., [@B46]) has recently revealed that the mitochondrial membrane protein UCP2 controls satiation vs. continued clearance of apoptotic cells, and it would be interesting to examine its role in the generation of CD11b^low^ macrophages. The integration of the results from Schif-Zuck et al., Bystrom et al., and Stables et al. suggests rM/CD11b^high^ macrophages are a mixed macrophage population with dominant M2-like characteristics, and some low-grade M1 activity and that early efferocytosis promotes the conversion of the M1-like population to an M2-like phenotype (Fadok et al., [@B13]; Freire-De-Lima et al., [@B16]; Korns et al., [@B28]) as well as enhanced phagocytosis/efferocytosis. However, the CD11b^low^ subset of macrophages, although converting from the CD11b^high^ subset *ex vivo* and *in vivo* (following late, threshold-meeting, efferocytosis; Schif-Zuck et al., [@B55]), are not M2-like, but rather display a distinct phenotype with its own molecular and functional characteristic (Figure [1](#F1){ref-type="fig"}). Of interest, a similar series of macrophage phenotype switches was found to take place during muscle injury and repair. These switches were induced by the engulfment of muscle debris that promoted TGFβ production and muscle regeneration (Arnold et al., [@B5]; Perdiguero et al., [@B48]). Importantly, the macrophage phenotype switch was mediated by a signaling cascade involving MAPK (Perdiguero et al., [@B48]) an essential module in macrophage inflammatory signaling (Kim et al., [@B26]).

![**Macrophage phenotype conversions induced by efferocytosis**. A monocyte that infiltrated an inflamed tissue differentiates to a macrophage and adopts an M1-like phenotype previous to encounter with apoptotic PMNs **(A)**. Once it encounters apoptotic PMN and starts to engulf them (early efferocytosis), the macrophage switches to an M2-like phenotype that is anti-inflammatory, highly efferocytic, and involved in tissue repair and return to homeostasis, but can also promote fibrosis and scar formation **(B)**. As the engulfment of apoptotic PMN by the macrophage continues and reaches a threshold level determined by the resolving milieu (satiating-efferocytosis) the macrophage undergoes another switch to the Mres phenotype **(C)**. These macrophages reduce the expression of pro-fibrotic arginase-1 and display reduced phagocytosis of extracellular particle including apoptotic cells. Consequently, rapid Mres departure of the resolving tissue and emigration to remote sites takes place. At these target organs Mres macrophages presumably produce 12/15-LO-derived pro-resolving lipid mediators, and deliver homeostatic signals to antigen presenting cells and lymphocytes. Moreover, Mres that stay in the resolving tissue might express higher levels of anti-inflammatory, anti-fibrotic, and anti-oxidant proteins to limit tissue damage and fibrosis. 12/15-LO-derived lipid mediators probably also contribute to the anti-inflammatory and anti-fibrotic properties of Mres in the resolving tissue. Early and satiating-efferocytosis can be modulated by pro-resolving and anti-inflammatory mediators, such as lipoxins, resolvins, protectins, maresin, GC, IL-4, TGFβ, IL-10, and PPARγ ligands **(D)**. This modulation can enhance the immune-silencing and departure of Mres to the lymphatics, where they can contribute to the termination of acquired immune responses.](fimmu-03-00004-g001){#F1}

Macrophages are important in limiting inflammation, excessive tissue repair, and fibrosis (Wynn and Barron, [@B65]). They also act at remote sites, such as lymphoid organs and adipose tissue (Schwab et al., [@B56]; Mukundan et al., [@B42]; Odegaard et al., [@B45]; Titos et al., [@B61]) to regulate acquired immune responses and metabolism. Since CD11b^low^ macrophages are distinct from either M1 or M2, do not express the pro-fibrotic enzyme arginase-1, stop phagocytosing foreign particles and can be found at lymphoid organs and adipose tissue (Schif-Zuck et al., [@B55]; Titos et al., [@B61]), we suggest these macrophages display a new phenotype, now termed resolution-promoting macrophages (Mres), which might be involved in anti-fibrotic, immune-regulatory, and metabolic processes, and hence is critical for the local and systemic termination of inflammatory episodes. The "decision-making" of macrophages on which phenotype will be expressed at a given time and setting is probably controlled by multiple variants in their milieu, including the number of apoptotic PMN they acquired and local concentrations of pro-resolving lipid mediators (from 15-LO and other pathways) and glucocorticoids (Schif-Zuck et al., [@B55]; Titos et al., [@B61]). Other macrophage-inactivating and resolution-promoting cytokines, growth factors and lipid mediators, such as IL-10, TGFβ, and PPARγ ligands are likely to also be important in regulating the fate of macrophages during the resolution of inflammation and the return of tissues to homeostasis.
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